ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The ITHACA study is a phase I study evaluating the safety and toxicity of a peritumorally
injected PD-1 checkpoint inhibitor, in combination with a multifunctional CTLA-4 inhibitor,
in early-stage cervical cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)